[
  {
    "ts": null,
    "headline": "Yescarta速 Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025",
    "summary": "SANTA MONICA, Calif., December 07, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta速 (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).",
    "url": "https://finnhub.io/api/news?id=1ac597bc5f4aa736cf3e233dde5e195b12c5ff60a825292dd85f13c6fba37da9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765112400,
      "headline": "Yescarta速 Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025",
      "id": 137726491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., December 07, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta速 (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).",
      "url": "https://finnhub.io/api/news?id=1ac597bc5f4aa736cf3e233dde5e195b12c5ff60a825292dd85f13c6fba37da9"
    }
  },
  {
    "ts": null,
    "headline": "Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates",
    "summary": "Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue growth expectations eased from around 3.89% to 3.68%. These modest adjustments reflect analysts fine tuning their models in light of a more nuanced mix of tailwinds, such as extended HIV cash flows and a larger PrEP opportunity, and headwinds, such as execution risk in next generation programs and...",
    "url": "https://finnhub.io/api/news?id=676ca898fdc9947205c4e4805aaa7371942915759f2c6305e75e28691b17eeaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765095032,
      "headline": "Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates",
      "id": 137726492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue growth expectations eased from around 3.89% to 3.68%. These modest adjustments reflect analysts fine tuning their models in light of a more nuanced mix of tailwinds, such as extended HIV cash flows and a larger PrEP opportunity, and headwinds, such as execution risk in next generation programs and...",
      "url": "https://finnhub.io/api/news?id=676ca898fdc9947205c4e4805aaa7371942915759f2c6305e75e28691b17eeaf"
    }
  }
]